Global research trends and hotspots of Helicobacter pylori eradication based on clinical trial registration platforms: A cross-sectional analysis
Jia-Lun Guan,Li-Na Feng,Ying-Ying Han,Su-Hong Xia,Kai Zhao,Ming- Yu Zhang,Yu Zhang,Ruo-Nan Dong,Yu-Jie Huang,Ji-Yan Li,Jia-Zhi Liao,Pei-Yuan Li,Ming-Yu Zhang
DOI: https://doi.org/10.1016/j.clinre.2023.102233
IF: 3.189
2023-10-27
Clinics and Research in Hepatology and Gastroenterology
Abstract:Background This study aimed to obtain an overview of clinical trials on Helicobacter pylori ( H. pylori ) eradication and analyze the global trends and hotspots in this field. Methods We collected the data from clinical trials focused on H. pylori eradication in the primary clinical trial registries from 2000 to 2022 in the world. Then we analyzed the research trends and hotspots in H. pylori eradication regimens in different regions at different periods. Results A total of 780 clinical trials were included, which were mainly conducted in Asia (682), followed by Europe (59), Africa (20), North America (16), South America (7), Oceania (2). The most active countries were China (343), Iran (140), South Korea (63), and Japan (73). "Bismuth-containing quadruple therapy (BQT)" was the most studied regimen (159, 20.38 %). Additionally, clinical trials focused on potassium-competitive acid blockers (P-CABs)-based therapy, probiotics, and high-dose dual therapy (HDDT) were constantly increasing. BQT received the most attention in China (26.53 %) and Iran (22.14 %), while it was tailored therapy in South Korea (23.29 %). P-CABs-based therapy was the main reseach hotspot in Japan (61.90 %). Conclusion How to eradicate H. pylori infection has been a heated research topic. BQT, P-CABs-based therapy, probiotics, and HDDT attracted the most attention in recent years.
gastroenterology & hepatology